Featured News
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Local company unveils blood test to find treatments for chronic pain
Local company unveils blood test to find treatments for chronic pain
AMPEL BioSolutions Enters MDx Market With Lupus, Dermatology Gene Expression Assays
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
COMPANY NEWS
From Genomic Tests to AI Predictions: Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions, Joins BioTalk
Tune in to this exciting episode of BioTalk with Rich Bendis, featuring Dr. Amrie Grammer, Co-Founder of AMPEL BioSolutions. In this enlightening discussion, Dr. Grammer unveils the secrets behind AMPEL’s remarkable success in precision medicine, making this episode a must-listen.
Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth
The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements.
First Lady of Virginia visits AMPEL
Suzanne Youngkin shared the goals of the W+g initiative focused on wellbeing and workforce in Virginia during her March 30th visit to AMPEL BioSolutions, a women-owned business founded, headquartered and growing in Charlottesville. The focus of AMPEL's business is...
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.
Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
Eight Innovative, Virginia Life Science Startups to Know
There are a host of exciting, innovative startup companies that call Charlottesville home. We’re excited to highlight these nine innovative Charlottesville, Virginia startup companies and look forward to telling their stories well into the future.
Trial of LuPRO mobile app predicts Lupus flares
CLICK TO VIEW ORIGINAL ARTICLE > BY KATIE O'CONNOR, Richmond Times-Dispatch In 50 years, only one treatment was approved by the U.S. Food and Drug Administration to treat lupus, an autoimmune disease in which a person’s immune system attacks their healthy organs...
Dr. Amrie Grammer of AMPEL BioSolutions joins host Rich Bendis on BioTalk
CLICK TO VIEW ARTICLE & WATCH VIDEO > AMPEL BioSolutions Co-Founder and COO/CSO, Dr. Amrie Grammer guests on BioTalk to discuss building the Company in Charlottesville, VA, her work and recognition at NIH, and being a leader from the southern part of the...
Cville Company Uses Genetics and Big Data to Find Better Medical Treatments
CLICK TO READ AND LISTEN TO ARTICLE > Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show. Now, however, a Virginia company is taking a different...
UVA Students & Alums Succeed at AMPEL
CLICK TO VIEW ALUMNI BIOS >
Q&A: UVA-Trained Biotech Leader Setting Her Sights on Lupus
CLICK TO READ ORIGINAL ARTICLE > by Fariss Samarrai, farisss@virginia.edu Lupus is a complex autoimmune disease that affects more than 1.4 million Americans. Its treatment in the United States alone costs about $7 billion per year. Despite this impact and cost, the...